StockData
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31

Immunovant, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.62+0.89 (+3.33%)

Close on Oct 19, 2026

Market cap
$5.68B
P/E (TTM)
–
Dividend yield
–

Immunovant, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Immunovant does not break out revenue by segment, region or product in the tagged data of its filings for this period type.